



## Original Article

## Radon, Tobacco Exposure and Non-Small Cell Lung Cancer Risk Related to BER and NER Genetic Polymorphisms<sup>☆</sup>



José Ramón Enjo-Barreiro<sup>a,b,c</sup>, Alberto Ruano-Ravina<sup>b,c,d,\*</sup>, Mónica Pérez-Ríos<sup>b,c,d</sup>, Karl Kelsey<sup>e</sup>, Leonor Varela-Lema<sup>b</sup>, María Torres-Durán<sup>f</sup>, Isaura Parente-Lamelas<sup>g</sup>, Mariano Provencio-Pulla<sup>h</sup>, Iria Vidal-García<sup>i</sup>, María Piñeiro-Lamas<sup>c</sup>, José A. Fernández-Villar<sup>g</sup>, Juan M. Barros-Dios<sup>a,b,c</sup>

<sup>a</sup> Service of Preventive Medicine, University Complex of Santiago de Compostela, Spain

<sup>b</sup> Department of Preventive Medicine, Santiago de Compostela University Teaching Hospital Complex, Santiago de Compostela, Spain

<sup>c</sup> Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain

<sup>d</sup> Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela-IDIS), Santiago de Compostela, Spain

<sup>e</sup> Department of Epidemiology, Brown School of Public Health, Brown University, Providence, Rhode Island, USA

<sup>f</sup> Service of Neumology, University Hospital Complex of Vigo, Spain

<sup>g</sup> Service of Neumology, University Hospital Complex of Ourense, Spain

<sup>h</sup> Service of Medical Oncology, Puerta del Hierro University Hospital of Madrid, Spain

<sup>i</sup> Service of Neumology, University Hospital Complex of A Coruña, Spain

## ARTICLE INFO

## Article history:

Received 22 April 2021

Accepted 14 July 2021

Available online 27 July 2021

## Keywords:

Non-small cell lung cancer

Smokers

Non-smokers

Genetic polymorphisms

Radon

## ABSTRACT

**Introduction:** Tobacco consumption and radon exposure are considered the first and second most common causes of lung cancer, respectively. The aim of this study was to analyze both whether selected genetic polymorphisms in loci that are in DNA repair pathways, are related to non-small-cell lung cancer (NSCLC) and whether they may modulate the association between residential radon exposure and lung cancer in both smokers and never smokers.

**Methods:** A multicentre, hospital-based, case-control study with 826 cases and 1201 controls was designed in a radon-prone area. Genotyping was determined in whole blood and residential radon exposure was measured in participants' dwellings.

**Results:** Attending to tobacco exposure, the variant in the gene *NBN* (rs1805794) was associated with lung cancer in never smokers (OR 2.72; 95%CI 1.44–5.2) and heavy smokers (OR 3.04; 95%CI 1.21–7.69). The polymorphism with the highest lung cancer association was *OGG1* (rs125701), showing an OR of 8.04 (95%CI 1.64–58.29) for its homozygous variant genotype in heavy smokers. Attending to indoor radon exposure (>200 Bq/m<sup>3</sup>), rs1452584, for its homozygous variant genotype, showed the highest association (OR 3.04 (95%CI 1.15–8.48)).

**Conclusion:** The genes analyzed seem to have no association with the fully adjusted model, but they might modulate lung cancer association when different categories of tobacco consumption are considered (i.e. heavy smokers). This association may similarly be elevated for those individuals having high indoor radon exposures, though at a minor extent.

© 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

### El radón, la exposición al tabaco y el riesgo de desarrollar cáncer de pulmón de células no pequeñas en relación con polimorfismos genéticos de BER y NER

## RESUMEN

**Introducción:** El consumo de tabaco y la exposición al radón se consideran la primera y la segunda causa más frecuentes de cáncer de pulmón, respectivamente. El objetivo de este estudio fue analizar si determinados polimorfismos genéticos en los loci que forman parte de la cascada de reparación del ADN se asocian con el cáncer de pulmón de célula no pequeña, y también si es posible que modifiquen la

## Palabras clave:

Cáncer de pulmón de células no pequeñas

Fumadores

No fumadores

<sup>☆</sup> This article is part of José Ramón Enjo-Barreiro doctoral thesis.

\* Corresponding author.

E-mail address: [alberto.ruano@usc.es](mailto:alberto.ruano@usc.es) (A. Ruano-Ravina).

Polimorfismos genéticos  
Radón

asociación entre la exposición al radón en el hogar y el cáncer de pulmón tanto en fumadores como en no fumadores.

**Métodos:** Se diseñó un estudio multicéntrico hospitalario de casos y controles con 826 casos y 1.201 controles en un área proclive a la presencia de radón. Se determinó el genotipo en sangre y se midió la exposición al radón en el lugar de residencia de los participantes.

**Resultados:** Analizando la exposición al tabaco, la variante del gen *NBN* (rs1805794) se asoció con el cáncer de pulmón en no fumadores (OR 2,72; IC 95% 1,44-5,2) y grandes fumadores (OR 3,04; IC 95% 1,21-7,69). El polimorfismo con mayor asociación con el cáncer de pulmón fue *OGG1* (rs125701), con una OR de 8,04 (IC 95% 1,64-58,29) para la variante genotípica en homocigosis en grandes fumadores. En cuanto a la exposición al radón en interiores (> 200 Bq/m<sup>3</sup>), rs1452584 en homocigosis mostró la asociación más fuerte (OR 3,04; IC 95% 1,15-8,48).

**Conclusión:** Los genes que se analizaron no muestran asociación con el modelo completamente ajustado, pero podrían modificar la asociación con el cáncer de pulmón cuando se consideran diferentes categorías de consumo de tabaco (esto es, grandes fumadores). Esta asociación podría aumentar de forma similar en aquellos individuos que están expuestos al radón en interiores, aunque en menor medida.

© 2021 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Worldwide, lung cancer represents 11.4% of overall cancer diagnoses. It is also the leading cause of cancer death, accounting for 18% of all cancer deaths. It is the most frequently occurring cancer among men and the third most frequent in women. Lung cancer is the leading cause of cancer death among men and the second most common fatal cancer in women, comprising 21.5 and 13.7% of all cancer deaths, respectively.<sup>1,2</sup> Tobacco consumption is the main association factor of this disease followed by exposure to indoor radon.<sup>2</sup>

Radon is classified as the main cause of lung cancer in never smokers and the second most common in ever-smokers by the United States Environmental Protection Agency (USEPA) and the World Health Organization (WHO).<sup>3–5</sup> The molecular mechanism of radon carcinogenesis is not fully understood, and lack of knowledge remains regarding the precise molecular carcinogenic pathways for tobacco exposure. Genetic susceptibility may play an important role and explains why some people develop lung cancer and others do not, given the same tobacco or indoor radon exposures.<sup>6,7</sup>

Tobacco smoke, despite damaging DNA, has an additional effect in DNA repair pathway activity, reducing the detectable amount of some repair proteins, (including XPC, OGG1 and OGG2) in pulmonary tissue in mouse models.<sup>8</sup> Tobacco smoke exposure induces bulky DNA adducts, which have a linear relationship with carcinogenesis at low exposure, but with high doses may reach a steady state, possibly due to DNA repair pathway saturation and increased apoptosis.<sup>9,10</sup>

Low capacity in DNA repair is related with an increased association with lung cancer.<sup>11,12</sup> There are three major types of DNA repair mechanisms: nucleotide excision repair (NER), the main route in mammals which repair DNA damaged by ultraviolet light, environmental mutagens and chemotherapy<sup>12</sup>; base excision repair (BER) that repairs DNA damaged by oxidation, deamination and alkylation. It protects from ageing, neurodegeneration and cancer<sup>13</sup>; and mismatch repair (MMR) that blocks recombination between non identical DNA.<sup>14</sup> Published studies have focused in genes involved in NER such as ERCC1 and ERCC2, BER such as XRCC1 and OGG1, and MMR such as XRCC3.<sup>15</sup> Nevertheless, no study has analyzed the potential interplay between these molecular pathways and indoor radon exposure.

The aim of this study was to analyze if selected genetic polymorphisms in genes playing a role in these molecular pathways are associated with an increased association of NSCLC. As a secondary objective, we have analyzed the effect of these genes taking into account the different amount of tobacco consumption and indoor radon exposure, to ascertain a potential modulating effect for the polymorphisms analyzed.

## Subjects and methods

### Design, subjects and settings

A multicentre, hospital-based, case-control study was conducted in 12 Spanish hospitals located in four different regions. The population was insured by the National Health Service. Lung cancer diagnosis was pathologically confirmed in their respective hospitals of reference. Cases and controls were recruited between January 2011 and October 2018. All patients had to be at least 30 years old, with no upper limit to participant age. Subjects with a previously history of cancer were excluded. To be included as a case, the patient had to have a pathologically confirmed primary lung cancer. Small Cell Lung Cancer patients were excluded. Controls were individuals undergoing minor, non-oncological, ambulatory surgery not related to tobacco consumption. Controls were recruited using frequency-based age and sex matching with cases in order to ensure a similar distribution between cases and controls. We have used this approach previously.<sup>6,16</sup> The study protocol was approved by the Santiago de Compostela Committee of Research Ethics (reference 2010/295 and 2013/364). Written informed consent was obtained for all participants.

### Data collection and radon measurements

All participants answered a questionnaire administered through personal interview regarding their lifestyle, with especial emphases on smoking habit and indoor radon. A detailed smoking history was obtained through interview. Radon was measured in the dwellings of participants. The return rate of radon devices was higher than 87% for both cases and controls. The Galician Radon Laboratory ([www.radon.gal](http://www.radon.gal); School of Medicine, University of Santiago de Compostela, Galicia, Spain) read the detectors. This is one of three laboratories certified by the National Entity of Accreditation to measure indoor radon in Spain.

### Laboratory methods

Twenty-four single nucleotide polymorphisms (SNP) in fifteen genes and one SNP in a non-protein-coding RNA (ncRNA) region of chromosome 18 involved in DNA repair were investigated. The genes analyzed involved in DNA repair were: *ERCC1* (rs11615, rs3212986), *ERCC2* (rs13181, rs1799793), *ERCC3* (rs3738948, rs4150459), *ERCC5* (rs1047768, rs2094258), *OGG1* (rs1052133, rs2072668, rs2472037, rs125701), *APEX1* (rs1130409, rs3136817), *XRCC1* (rs25487), *XRCC3* (rs861539), *MUTYH* (rs3219489), *NBN* (rs1805794), *RRM1* (rs12806698), *XPC*

(rs2228001), *KLH4* (rs5922437) and *FATS* (rs11245007). In addition, we included in this study the single-nucleotide variation in intronic region rs1452584, located in chromosome 18, q21.33, which is in a ncRNA gene, these regions might have regulatory functions.<sup>17</sup>

Genetic polymorphisms in the studied genes (were analyzed from DNA extracted from 3 ml of whole blood donated by the participants. Genotyping was performed at the CeGen, which is one of the three genotyping core facilities of the National Genotyping Centre (belonging to the University of Santiago de Compostela).

SNPs were studied with MassARRAY® System developed by Agena Bioscience Inc., a technology which make possible the investigation of the presence of punctual variants of DNA.<sup>18</sup>

### Statistical analysis

A bivariate descriptive analysis was performed comparing the characteristics of cases and controls. We performed a multiple logistic regression in which the dependent variable was the case or control status of the participants and the main independent variables were the SNPs studied. Results were adjusted by age and sex in the first model. Tobacco consumption and indoor radon exposure were added to the previous variables creating a fully adjusted model. The homozygote polymorphism genotype of the common allele (wild type) was used as the reference group.

To assess the existence of a relationship between selected genetic polymorphisms and tobacco consumption, we stratified smoking habit in three categories (never smokers, moderate smokers (second tercile: 34–66 packs-years) and heavy smokers (third tercile: >66 packs-year) and each polymorphism in three different genotypes (homozygous for the common allele (wild type), heterozygous and homozygous for the mutation). In addition, we studied whether lung cancer association was modified between the same polymorphisms and radon indoor exposure stratifying this variable in two categories ( $\leq 200$  Bq/m<sup>3</sup> and  $>200$  Bq/m<sup>3</sup>). Stratification at 200 Bq/m<sup>3</sup> was applied since previous studies have demonstrated that the association of lung cancer was increased at this dose.<sup>19,20</sup> All statistical results are expressed as Odds Ratios (OR) with their 95% confidence intervals. Statistical analyses were performed with IBM SPSS v22 (IBM, Armonk, NY, USA). We included in the tables the *p*-values and we corrected them applying the False Discovery Rate because to reduce the possibility of false positive results due to multiple comparisons.

### Results

The study included 2027 participants, 826 cases and 1201 controls. Cases and controls were well balanced regarding sociodemographic variables, with an average age of 65.5, 50.5% of women. Cases and controls lived a similar number of years in the same dwelling. Residential radon exposure was available for 754 cases (91.3%) and 1010 controls (84.1%). The most frequent histological type was adenocarcinoma (69.7%). A sample description broken down by case–control status is shown in Table 1.

Table 2 summarizes the results for the different genotypes and their distribution between cases and controls. Compared to participants with wild type gene *NBN* (rs1805794) showed an OR for the homozygous genotype of 1.78 (95%CI 1.23–2.58) and 1.78 (95%CI 1.15–2.75) after adjustment for age and sex and full adjustment, respectively. This result along other results for other polymorphisms showing no association are shown in Table 2.

Table 3 shows the association of the different polymorphisms studied with lung cancer at varying tobacco exposure categories (never-smokers, moderate-smokers and heavy-smokers). Lung cancer association increases when participants are heavy smokers for almost all the polymorphisms analyzed. Compared with

never-smokers, the highest OR corresponded to homozygous genotype in heavy smokers for: *OGG1* (rs125701) (OR 8.04; 95%CI 1.64–58.29), *OGG1* (rs2472037) (OR 6.1; 95%CI 2.3–17.5) and *ERCC1* (rs32112986) (OR 5.92; 95%CI 1.59–28.18). Only *ERCC3* (rs4150459) in its homozygous type expressed an increased association with NSCLC in moderate smokers compared with never smokers with wild type (OR 2.9; 95%CI 1.96–4.33). *NBN* (rs1805794) in its homozygous genotype showed a higher association with lung cancer in never smokers (OR 2.72; 95%CI 1.44–5.2).

Table 4 shows the association of these polymorphisms with lung cancer broken down by radon concentration ( $\leq 200$  Bq/m<sup>3</sup> and  $>200$  Bq/m<sup>3</sup>). NSCLC associations were increased for some variants for those participants exposed to more than 200 Bq/m<sup>3</sup>. rs1452584 showed the highest association for the homozygous genotype (OR 3.04; 95% CI 1.15–8.48) as well as *APEX1* (rs1130409) and *ERCC1* (rs11615) showed a higher association too (OR 1.68; 95% CI 1.04–2.73 and OR 1.65; 95%CI 1.1–2.48 respectively). *XRCC3* (rs861539), *ERCC2* (rs13181), *OGG1* (rs10521333) and *ERCC1* (rs3212986) showed this increase for the heterozygous form (OR 1.79; 95%CI 1.28–2.51, OR 1.56; 95%CI 1.13–2.15, OR 1.53; 95%CI 1.09–2.16 and OR 1.47; 95%CI 1.06–2.04, OR 1.47; 95% CI 1.06–2.04 respectively). In addition, *NBN* (rs1805794) showed an increased association for its homozygous genotype for low indoor radon exposures (OR 1.88; CI 95% (1.09–3.24). No other significant association was observed.

### Discussion

We found that the association with lung cancer may be modulated by different genetic polymorphisms in the BER and NER pathways. These polymorphisms appear to have the most prominent effect when they are homozygous in heavy smokers. Some polymorphisms could also increase NSCLC association in those individuals exposed to high radon concentrations. To our knowledge, this is the study with the largest number of DNA repair genes analyzed involved in lung cancer related to radon exposure. It also provides potentially valuable data for further understanding of the carcinogenic pathway of tobacco consumption. The sample size of our study is large, with 2027 participants including smokers, never smokers and indoor radon exposure, and expands a previous study performed exclusively in never smokers.<sup>7</sup>

We have observed that participants considered heavy smokers, globally, had an increased association with lung cancer compared with the wild type in never smokers. The polymorphism most associated with NSCLC was rs125701 (*OGG1*) in its homozygous variant form. Attending to the study of Hualong Qin et al. this polymorphism is frequently methylated in NSCLC, but in that study no significant result was obtained. This could be due to the absence of homozygous participants for this gene. In contrast with our study, it was performed only in Chinese population.<sup>21</sup> A relevant association was also observed for rs2472037 and rs3212986, both in the *OGG1* gene, for its homozygous genotypes, increasing the association of lung cancer in heavy smokers. Regarding rs3212986, this polymorphism is considered an important contributor to lung cancer development in smokers.<sup>22,23</sup> In addition, no relation with never smokers was detected by Tau Yu et al.<sup>23</sup>

The *NBN* gene variant (rs1805794), located in MMR pathway, was also associated with an increased association with lung cancer in heavy smokers in accordance with Chuang et al.,<sup>24</sup> though they only found association in male smokers. The homozygous mutation of this gene in heavy smokers shows a higher lung cancer association compared to never smokers. These results are similar to the obtained by Charlotta et al.<sup>25</sup> who found an increased lung cancer association in never smoking women and smoking women with low tobacco consumption. The increased lung cancer

**Table 1**  
Sample description broken down by case–control status.

Variable	Cases, n (%)	Controls, n (%)
Number of patients	826 (40.7%)	1201 (59.3%)
Median age (range)/25–75 <sup>th</sup> percentile	67 (25–94)/59–74	64 (21–92)/56–72
Sex		
Female	417 (50.5)	553 (46)
Male	409 (49.5)	648 (54)
Education		
No formal studies	164 (20.3)	191 (16)
Primary School	402 (49.7)	609 (51.1)
High School	135 (16.7)	236 (19.8)
University degree	108 (13.3)	156 (13.1)
Tobacco consumption		
Never-smokers	428 (57.3)	708 (61.3)
Light smokers (first tertile, 1–33 pack-years)	86 (11.5)	266 (23)
Moderate smokers (second tertile, 34–66 pack-years)	132 (17.7)	128 (11.1)
Heavy smokers (third tertile, >66 pack-years)	101 (13.5)	53 (4.6)
Residential radon exposure Bq/m <sup>3</sup>		
≤100	190 (25.2)	300 (29.7)
101–147	141 (18.7)	210 (20.8)
148–199	116 (15.4)	155 (15.3)
≥200	307 (40.7)	345 (34.2)
Geometric mean (95% CI)	166.18 (156.94–175.96)	152.58 (145.18–160.36)
Median (25–75th percentiles)	164.5 (99.8–280.3)	146 (90.8–254.3)
Years (median) living in the measured dwelling/25–75th percentiles	28 (14–40)	30 (15–40)
Histological types		
Adenocarcinoma	573 (69.7)	
Squamous cell carcinoma	154 (18.7)	
Large cell carcinoma	29 (3.5)	
Other histological types	66 (8)	

association shown in our study is similar to that reported by the Wang et al. meta-analyses.<sup>26</sup> In contrast, He et al. did not find any similar association.<sup>27</sup> This gene is known to take part in other carcinogenic procedures such as ovarian, breast and colorectal cancer. In addition, it has been studied for clinical purposes in the testing of hereditary cancers.<sup>28</sup>

In general, our results note that a number of genetic polymorphisms are associated with increased lung cancer association when these polymorphisms are homozygous. This was apparent for a number of the analyzed genes, especially those in the NER pathway. This could be attributable to the importance of this pathway in the repair of bulky DNA lesions generated by environmental mutagens.<sup>12</sup> The gene which showed a clear increase in NSCLC, compared to the wild type in heavy smokers, belonging to this pathway is *ERCC1* (rs3212986). *OGG1* polymorphisms rs125701 and rs2472037 showed the same effect but they are located in the BER pathway, which is specialized in repairing adducts originated by oxidation.<sup>13</sup> This is one of the main routes through which tobacco smoke produces DNA adducts.<sup>8,29</sup> This is interesting because there seems to be no association when we analyze these polymorphisms in the overall sample. Nevertheless, when we stratify the sample by smoking categories, we observe that for heavy smokers an association is present for some homozygous polymorphisms, suggesting a saturation effect on the anticarcinogenic pathways compared to wild type genes.

In relation with indoor radon exposure, we observed that participants exposed to more than 200 Bq/m<sup>3</sup> showed an increased lung cancer association for some of the polymorphisms studied. Only three of them showed an increased lung cancer association for their homozygous genotype: rs1452584, located in chromosome 18, showed the highest association; *ERCC1* (rs11615), located in NER pathway, which also showed an increased association for its wild type and *APEX1* (rs1130409), located in BER pathway. The results obtained for *ERCC1* are in accordance to the obtained by Lorenzo-González et al.<sup>8</sup> though this study is limited to a never

smoking population while ours includes also ever-smokers. Other polymorphisms showed higher association for their heterozygous genotype; one of them, located in the NER pathway, *ERCC1* (rs3212986) showed similar results to those found by Lorenzo-González et al.<sup>7</sup>

Despite the fact that some studies established a relationship between lung cancer association and DNA repair genes,<sup>22,30</sup> we are not aware of any study relating these polymorphisms with indoor radon exposure. These findings support our hypothesis that lung cancer association is increased by indoor radon exposure and that some variants might have a special importance favouring the development of this disease.

This research has some limitations. The most important limitation is that when we correct the *p*-value with the false discovery rate, we observed that some “suggestive” *p*-values in different genes become “non-suggestive”, but it is important to resemble that a “non-suggestive” association cannot be deduced only by a *p*-value because it could be easily modified. For example, if we have a small number of participants in one category, we might have a “non-suggestive” *p*-value and a suggestive confidence interval. If we increase the number of participants in the category we could have a significant *p*-value while the width of the confidence interval narrows. Secondly, we did not have enough participants in some polymorphisms, which makes difficult to establish a potential association with lung cancer. One example is *ERCC3* (rs4150459) that for its homozygous genotype for never-smokers did not have enough participants to obtain any result. Other limitations reside in the limited number of polymorphisms we have assessed. Not all polymorphisms present in the studied genes have been analyzed, and the BER and NER pathways have some more genes that we do not have analyzed. A further limitation is the fact that there are other pathways and genes involved in carcinogenesis that we do not have included and might have a role, such as deletion of *GSTM1* and *GSTT1* genes.<sup>31</sup> Finally, the most frequent histological type was adenocarcinoma. This is due to the fact that we included an



**Table 2**  
Lung cancer association broken down by the different polymorphisms analyzed.

Polymorphism Allele	Cases, n (%)	Controls, n (%)	OR <sup>a</sup> (95%CI)	p <sup>c</sup>	p-c <sup>d</sup>	OR <sup>b</sup> (95%CI)	p <sup>e</sup>	p-c <sup>d</sup>
<i>ERC55_rs1047768</i>								
TC	220 (49.3)	312 (46.1)	1 (-)			1 (-)		
CC	150 (33.6)	229 (33.8)	0.94 (0.73–1.2)	0.6269	0.6697	0.98 (0.74–1.31)	0.9121	0.7469
TT	76 (17)	136 (20.1)	0.71 (0.52–0.96)	0.0271	0.1141	0.71 (0.49–1.01)	0.0583	0.1943
<i>OGG1_Ser326Cys_rs1052133</i>								
CC	391 (62.2)	577 (61)	1 (-)			1 (-)		
CG	209 (33.2)	307 (32.5)	0.92 (0.75–1.12)	0.4076	0.5687	0.99 (0.79–1.24)	0.9288	0.7503
GG	29 (4.6)	62 (6.6)	0.66 (0.43–1.01)	0.0598	0.1974	0.63 (0.39–1.02)	0.0638	0.2055
<i>FATS_C10orf90_rs11245007</i>								
CT	207 (46.4)	301 (44.4)	1 (-)			1 (-)		
CC	205 (46)	311 (45.9)	0.98 (0.78–1.24)	0.8933	0.7429	0.92 (0.70–1.21)	0.5505	0.6404
TT	34 (7.6)	66 (9.7)	1.01 (0.68–1.5)	0.9683	0.758	0.78 (0.48–1.25)	0.3116	0.502
<i>APEX1_rs1130409</i>								
GT	208 (46.6)	329 (48.5)	1 (-)			1 (-)		
TT	125 (28)	187 (27.6)	1.02 (0.78–1.33)	0.8805	0.7401	1.17 (0.86–1.6)	0.3074	0.4986
GG	113 (25.3)	162 (23.9)	1.03 (0.78–1.36)	0.8138	0.7247	1.14 (0.83–1.58)	0.4147	0.5729
<i>ERCC1_rs11615</i>								
CC	153 (24.2)	226 (23.9)	1 (-)			1 (-)		
CT	248 (39.3)	413 (43.6)	1.01 (0.79–1.28)	0.9469	0.7539	0.91 (0.69–1.2)	0.4948	0.6155
TT	230 (36.5)	308 (32.5)	1.25 (0.97–1.61)	0.0838	0.2435	1.16 (0.87–1.54)	0.3188	0.5077
<i>OGG1_rs125701</i>								
GG	328 (73.5)	497 (73.4)	1 (-)			1 (-)		
AG	103 (23.1)	165 (24.4)	0.89 (0.68–1.16)	0.3889	0.5571	0.93 (0.69–1.26)	0.6522	0.6784
AA	15 (3.4)	15 (2.2)	1.65 (0.84–3.28)	0.1466	0.3362	1.62 (0.73–3.57)	0.2321	0.4288
<i>RRM1_rs12806698</i>								
CC	248 (55.6)	388 (57.2)	1 (-)			1 (-)		
CA	170 (38.1)	252 (37.2)	0.99 (0.78–1.24)	0.9033	0.745	1.01 (0.77–1.32)	0.9587	0.7562
AA	28 (6.3)	38 (5.6)	0.97 (0.59–1.57)	0.8909	0.7424	1.08 (0.62–1.87)	0.7764	0.7152
<i>ERCC2_Lys751Gln_rs13181</i>								
TT	272 (43.1)	426 (45)	1 (-)			1 (-)		
GT	281 (44.5)	416 (43.9)	1.09 (0.9–1.33)	0.388	0.5565	1.05 (0.84–1.32)	0.6465	0.6765
GG	78 (12.4)	105 (11.1)	1.17 (0.87–1.57)	0.3074	0.4986	1.1 (0.78–1.55)	0.6004	0.6601
<i>rs1452584</i>								
AA	281 (63)	465 (68.6)	1 (-)			1 (-)		
GA	183 (30.9)	189 (27.9)	1.08 (0.85–1.38)	0.52	0.6271	1.17 (0.88–1.55)	0.2936	0.4871
GG	27 (6.1)	24 (3.5)	1.45 (0.85–2.48)	0.1687	0.3624	1.61 (0.87–2.98)	0.126	0.3089
<i>ERCC2_Asp312Asn_rs1799793</i>								
TT	265 (59.4)	419 (61.9)	1 (-)			1 (-)		
CT	157 (35.2)	224 (33.1)	1.15 (0.91–1.46)	0.2468	0.4439	1.2 (0.91–1.58)	0.1948	0.3897
CC	24 (5.4)	34 (5)	1.04 (0.63–1.69)	0.8741	0.7387	1.03 (0.57–1.86)	0.9137	0.7472
<i>NBN_rs1805794</i>								
CC	188 (42.2)	313 (46.2)	1 (-)			1 (-)		
GC	202 (45.3)	304 (44.8)	1.06 (0.83–1.34)	0.6549	0.6793	1.09 (0.83–1.43)	0.5338	0.6332
GG	56 (12.6)	61 (9)	1.78 (1.23–2.58)	0.0022	0.0152	1.78 (1.15–2.75)	0.0102	0.0578
<i>OGG1_C7G_rs2072668</i>								
CC	274 (61.4)	405 (59.9)	1 (-)			1 (-)		
CG	150 (33.6)	228 (33.7)	0.88 (0.69–1.11)	0.2811	0.4762	0.96 (0.73–1.26)	0.7614	0.7112
GG	22 (4.9)	43 (6.4)	0.71 (0.42–1.15)	0.1691	0.3628	0.69 (0.38–1.21)	0.2025	0.397
<i>ERCC5_rs2094258</i>								
CC	281 (63)	441 (65.1)	1 (-)			1 (-)		
CT	139 (31.2)	204 (30.1)	1.05 (0.83–1.34)	0.684	0.6887	1.09 (0.82–1.44)	0.5672	0.6472
TT	26 (5.8)	32 (4.7)	0.95 (0.56–1.59)	0.8535	0.7341	1.13 (0.62–2.02)	0.6896	0.6905
<i>XPC_rs2228001</i>								
GT	214 (48)	332 (49)	1 (-)			1 (-)		
TT	162 (36.3)	234 (34.6)	0.99 (0.77–1.26)	0.909	0.7462	1.08 (0.81–1.44)	0.5805	0.6525
GG	70 (15.7)	111 (16.4)	0.95 (0.68–1.31)	0.7516	0.7085	0.86 (0.59–1.24)	0.4135	0.5722
<i>OGG1_rs2472037</i>								
AG	202 (45.5)	317 (47.5)	1 (-)			1 (-)		
AA	175 (39.4)	262 (39.2)	0.93 (0.73–1.18)	0.5533	0.6415	0.98 (0.74–1.3)	0.8976	0.7438
GG	67 (15.1)	89 (13.3)	1.16 (0.83–1.61)	0.3835	0.5537	1.31 (0.88–1.95)	0.1742	0.3685
<i>XRCC1_Gln399Arg_rs25487</i>								
GG	285 (45.2)	416 (43.9)	1 (-)			1 (-)		
AG	260 (41.2)	418 (44.1)	0.94 (0.77–1.14)	0.5226	0.6283	0.92 (0.74–1.16)	0.4951	0.6156
AA	86 (13.6)	113 (11.9)	1.15 (0.86–1.55)	0.3487	0.5301	1.12 (0.8–1.56)	0.5084	0.6218

Table 2 (Continued)

Polymorphism Allele	Cases, n (%)	Controls, n (%)	OR <sup>a</sup> (95%CI)	p <sup>c</sup>	p-c <sup>d</sup>	OR <sup>b</sup> (95%CI)	p <sup>c</sup>	p-c <sup>d</sup>
<b>APEX1_rs136817</b>								
TT	238 (53.4)	347 (51.2)	1 (-)			1 (-)		
CT	172 (38.6)	261 (38.5)	0.96 (0.76–1.22)	0.7614	0.7112	0.87 (0.66–1.14)	0.3021	0.4942
CC	36 (8.1)	70 (10.3)	0.73 (0.48–1.1)	0.1404	0.3284	0.75 (0.47–1.19)	0.229	0.4255
<b>ERCC1_rs3212986</b>								
GG	360 (57.1)	554 (58.5)	1 (-)			1 (-)		
GT	237 (37.6)	342 (36.1)	1.14 (0.94–1.39)	0.1867	0.3816	1.06 (0.85–1.33)	0.5942	0.6578
TT	34 (5.4)	51 (5.4)	1.06 (0.7–1.59)	0.7721	0.7141	1.1 (0.68–1.76)	0.7003	0.6937
<b>MUTYH_rs3219489</b>								
CC	243 (54.7)	351 (51.8)	1 (-)			1 (-)		
GC	163 (36.7)	281 (41.5)	0.92 (0.73–1.16)	0.4965	0.6163	0.85 (0.65–1.12)	0.2454	0.4425
GG	38 (8.6)	45 (6.6)	1.52 (0.98–2.35)	0.059	0.1958	1.41 (0.85–2.33)	0.1867	0.3816
<b>ERCC3_rs3738948</b>								
AA	268 (60.1)	406 (59.9)	1 (-)			1 (-)		
GA	150 (33.6)	242 (35.7)	0.92 (0.72–1.16)	0.4849	0.6107	1.04 (0.79–1.38)	0.7624	0.7115
GG	28 (6.3)	30 (4.4)	1.52 (0.93–2.49)	0.097	0.2654	1.42 (0.8–2.52)	0.2326	0.4293
<b>ERCC3_XPB_rs4150459</b>								
CC	406 (91)	604 (89.3)	1 (-)			1 (-)		
CT	39 (8.7)	69 (10.2)	0.96 (0.65–1.39)	0.8141	0.7248	0.77 (0.49–1.19)	0.2445	0.4416
TT	1 (0.2)	3 (0.4)	0.48 (0.02–3.78)	0.523	0.6285	0.45 (0.02–3.54)	0.4865	0.6114
<b>KLH4_rs5922437</b>								
GG	285 (63.9)	422 (62.3)	1 (-)			1 (-)		
AA	83 (18.6)	155 (22.9)	0.94 (0.71–1.24)	0.677	0.6865	0.88 (0.63–1.23)	0.4492	0.5923
GA	78 (17.5)	100 (14.8)	1.04 (0.72–1.51)	0.819	0.726	0.86 (0.57–1.29)	0.4693	0.6029
<b>XRCC3_Thr241Met_rs861539</b>								
CC	238 (37.8)	374 (39.5)	1 (-)			1 (-)		
TG	306 (48.6)	420 (44.4)	1.13 (0.93–1.39)	0.2284	0.4249	1.24 (0.98–1.56)	0.0687	0.2149
TT	86 (13.7)	152 (16.1)	0.91 (0.69–1.21)	0.5388	0.6354	0.89 (0.64–1.23)	0.497	0.6165

<sup>a</sup> Adjusted by age and sex.

<sup>b</sup> Adjusted by age, sex, tobacco consumption and indoor radon exposure.

<sup>c</sup> p-Values.

<sup>d</sup> Corrected p-values.

Table 3

Lung cancer association broken down by smoking status for the different polymorphisms analyzed.\*

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)								
	Never-smokers	p <sup>b</sup>	p-c <sup>c</sup>	Moderate smokers	p <sup>b</sup>	p-c <sup>c</sup>	Heavy smokers	p <sup>b</sup>	p-c <sup>c</sup>
<b>ERCC5_rs1047768</b>									
TC	92, 136			34, 106			56, 51		
	1 (-)			0.79 (0.48–1.3)	0.3592	0.5374	2.82 (1.7–4.71)	0.0001	0.0012
CC	62, 113			32, 71			29, 34		
	0.87 (0.57–1.34)	0.525	0.6294	1.1 (0.65–1.87)	0.7174	0.6988	2.1 (1.15–3.84)	0.0156	0.0789
TT	25, 57			9, 50			21, 18		
	0.58 (0.33–1.02)	0.0628	0.2035	0.45 (0.19–0.94)	0.0437	0.1604	2.64 (1.29–5.47)	0.0083	0.0491
<b>OGG1_Ser326Cys_rs1052133</b>									
CC	225, 353			41, 136			74, 60		
	1 (-)			0.7 (0.46–1.4)	0.0837	0.2433	2.82 (1.87–4.26)	<0.001	<0.001
CG	120, 183			30, 74			29, 38		
	0.98 (0.73–1.31)	0.876	0.7391	0.92 (0.56–1.47)	0.724	0.7008	1.77 (1.02–3.03)	0.0387	0.1471
GG	18, 39			2, 16			3, 5		
	0.64 (0.35–1.15)	0.147	0.3367	0.28 (0.04–1.02)	0.0975	0.2661	1.36 (0.27–5.7)	0.6809	0.6877
<b>FATS_C10orf90_rs11245007</b>									
CT	85, 132			37, 110			45, 43		
	1 (-)			0.84 (0.51–1.37)	0.4955	0.6158	2.74 (1.6–4.74)	0.0003	0.0027
CC	80, 144			32, 92			54, 52		
	0.88 (0.58–1.32)	0.5222	0.6281	0.93 (0.55–1.57)	0.7944	0.7199	2.62 (1.58–4.4)	0.0002	0.002
TT	14, 30			6, 25			7, 8		
	0.76 (0.36–1.54)	0.4158	0.5937	0.6 (0.21–1.48)	0.294	0.4874	2.27 (0.75–6.73)	0.1357	0.3222
<b>APEX1_rs1130409</b>									
GT	121, 176			6, 33			15, 11		
	1 (-)			0.39 (0.14–0.92)	0.2777	0.4732	3.32 (1.44–7.87)	0.0000	0.0027
TT	139, 233			32, 110			41, 52		
	0.91 (0.66–1.26)	0.5152	0.625	0.68 (0.41–1.1)	0.724	0.7008	1.82 (1.09–3.03)	0.017	0.0836
GG	103, 166			37, 84			50, 40		
	1.05 (0.74–1.48)	0.1551	0.3465	1.02 (0.62–1.64)	0.6638	0.6822	2.81 (1.7–4.7)	<0.001	<0.001

Table 3 (Continued)

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)								
	Never-smokers	p <sup>b</sup>	p-c <sup>c</sup>	Moderate smokers	p <sup>b</sup>	p-c <sup>c</sup>	Heavy smokers	p <sup>b</sup>	p-c <sup>c</sup>
<i>ERCC1_rs11615</i>									
CC	121, 176 1 (-)			6, 33 0.39 (0.14–0.92)	0.0459	0.1659	15, 11 3.32 (1.44–7.87)	0.0051	0.0326
CT	139, 233 0.91 (0.66–1.26)	0.5835	0.6537	32, 110 0.68 (0.41–1.1)	0.1206	0.3011	41, 52 1.82 (1.09–3.03)	0.0205	0.0952
TT	103, 166 1.05 (0.74–1.48)	0.8032	0.7221	37, 84 1.02 (0.62–1.64)	0.9504	0.745	50, 40 2.81 (1.7–4.7)	0.0001	0.0012
<i>OGG1_rs125701</i>									
GG	129, 215 1 (-)			60, 172 0.99 (0.66–1.49)	0.9734	0.7589	73, 76 2.64 (1.72–4.09)	<0.001	<0.001
AG	44, 82 0.91 (0.58–1.42)	0.6749	0.6858	13, 50 0.65 (0.32–1.24)	0.2071	0.4013	28, 25 3.11 (1.67–5.81)	0.0003	0.0027
AA	6, 9 1.13 (0.35–3.44)	0.8349	0.7298	2, 4 1.47 (0.2–7.77)	0.663	0.682	5, 2 8.04 (1.64–58.29)	0.0158	0.0796
<i>RRM1_rs12806698</i>									
CC	103, 162 1 (-)			44, 145 0.78 (0.5–1.23)	0.2938	0.4873	57, 59 2.46 (1.51–4.01)	0.003	0.0027
CA	64, 124 0.81 (0.53–1.22)	0.319	0.5078	28, 73 1 (0.58–1.69)	0.9928	0.7625	41, 37 2.91 (1.67–5.11)	0.0002	0.002
AA	12, 20 1.01 (0.45–2.21)	0.9741	0.7591	3, 9 0.82 (0.18–2.93)	0.7807	0.7163	8, 7 2.99 (1.02–9.01)	0.0453	0.1644
<i>ERCC2_Lys751Gln_rs13181</i>									
TT	157, 263 1 (-)			33, 103 0.84 (0.52–1.34)	0.4737	0.6051	50, 37 3.55 (2.16–5.9)	0.0000	0.0000
GT	165, 242 1.18 (0.89–1.57)	0.2502	0.4473	33, 104 0.77 (0.48–1.21)	0.2638	0.4604	42, 54 1.94 (1.2–3.13)	0.007	0.0427
GG	41, 70 0.94 (0.61–1.49)	0.8562	0.7347	9, 20 1.2 (0.5–2.68)	0.6745	0.6857	14, 12 2.89 (1.27–6.68)	0.0113	0.0625
<i>rs1452584</i>									
AA	106, 217 1 (-)			45, 149 0.99 (0.63–1.53)	0.9601	0.7564	72, 74 3.06 (1.97–4.78)	<0.001	<0.001
GA	61, 81 1.38 (0.9–2.12)	0.1367	0.3235	25, 68 1.13 (0.65–1.92)	0.6691	0.684	31, 25 3.88 (2.11–7.22)	<0.001	<0.001
GG	12, 8 2.36 (0.91–6.42)	0.0794	0.2356	5, 10 1.29 (0.38–3.92)	0.6656	0.6828	3, 4 2.49 (0.47–11.89)	0.2484	0.4455
<i>ERCC2_Asp312Asn_rs1799793</i>									
TT	119, 193 1 (-)			41, 132 0.83 (0.52–1.29)	0.4088	0.5694	62, 61 2.68 (1.68–4.28)	<0.001	<0.001
CT	53, 94 0.97 (0.63–1.49)	0.8854	0.7412	32, 87 1.03 (0.62–1.68)	0.9225	0.749	36, 35 2.9 (1.65–5.1)	0.0002	0.002
CC	7, 19 0.62 (0.23–1.54)	0.3232	0.5111	2, 8 0.64 (0.09–2.75)	0.5925	0.6571	8, 6 3.64 (1.18–11.81)	0.0249	0.1082
<i>NBN_rs1805794</i>									
CC	74, 144 1 (-)			35, 106 1.05 (0.63–1.74)	0.8462	0.7324	38, 44 2.87 (1.64–5.05)	0.0002	0.002
GC	76, 135 1.07 (0.7–1.62)	0.7615	0.7112	31, 99 1.12 (0.66–1.91)	0.6693	0.684	57, 48 4.04 (2.39–6.88)	<0.001	<0.001
GG	29, 27 2.72 (1.44–5.2)	0.0022	0.0152	9, 22 1.21 (0.49–2.78)	0.6632	0.6821	11, 11 3.04 (1.21–7.69)	0.0172	0.0843
<i>OGG1_C7G_rs2072668</i>									
CC	106, 181 1 (-)			43, 137 0.87 (0.55–1.37)	0.5564	0.6428	74, 60 3.41 (2.16–5.44)	<0.001	<0.001
CG	63, 105 0.97 (0.64–1.47)	0.8773	0.7394	29, 73 1.06 (0.62–1.78)	0.8262	0.7277	29, 38 2.03 (1.13–3.63)	0.0175	0.0852
GG	10, 20 0.74 (0.31–1.67)	0.4833	0.6099	3, 16 0.49 (0.11–1.56)	0.2759	0.4716	3, 5 1.45 (0.28–6.24)	0.6254	0.6692
<i>ERCC5_rs2094258</i>									
CC	118, 198 1 (-)			47, 144 0.88 (0.57–1.35)	0.5622	0.6452	64, 68 2.42 (1.54–3.82)	0.0001	0.0012
CT	53, 98 0.83 (0.54–1.27)	0.3909	0.5584	25, 69 0.97 (0.56–1.65)	0.9041	0.7452	35, 28 3.63 (2.02–6.59)	<0.001	<0.001
TT	8, 10 1.12 (0.4–3.14)	0.8216	0.7266	3, 14 0.51 (0.11–1.66)	0.3067	0.498	7, 7 2.42 (0.77–7.56)	0.1218	0.3028
<i>XPC_rs2228001</i>									
GT	86, 164 1 (-)			36, 106 1.02 (0.62–1.65)	0.9511	0.7547	51, 48 3.29 (1.97–5.53)	<0.001	<0.001
TT	65, 108 1.16 (0.76–1.77)	0.4977	0.6168	27, 82 1.08 (0.62–1.84)	0.7911	0.719	37, 25 4.78 (2.6–8.92)	<0.001	<0.001
GG	28, 34 1.45 (0.79–2.63)	0.2258	0.4221	12, 39 0.96 (0.45–1.95)	0.9217	0.7488	18, 30 1.8 (0.9–3.52)	0.0904	0.2548

Table 3 (Continued)

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)								
	Never-smokers	p <sup>b</sup>	p-c <sup>c</sup>	Moderate smokers	p <sup>b</sup>	p-c <sup>c</sup>	Heavy smokers	p <sup>b</sup>	p-c <sup>c</sup>
<i>OGG1_rs2472037</i>									
AG	73, 140 1 (-)			38, 105 1.17 (0.7–1.93)	0.5496	0.64	54, 55 3.11 (1.86–5.24)	<0.001	<0.001
AA	75, 121 1.15 (0.75–1.77)	0.5187	0.6266	25, 84 0.91 (0.51–1.58)	0.7425	0.706	39, 41 2.98 (1.69–5.28)	0.0002	0.002
GG	30, 38 1.73 (0.96–3.13)	0.0678	0.2132	11, 36 1.04 (0.47–2.18)	0.9197	0.7484	13, 7 6.1 (2.3–17.5)	0.0004	0.0034
<i>XRCC1_Gln399Arg_rs25487</i>									
GG	169, 257 1 (-)			32, 94 0.78 (0.48–1.24)	0.2954	0.4886	45, 45 2.28 (1.4–3.7)	0.0009	0.007
AG	145, 247 0.89 (0.67–1.19)	0.4299	0.5817	36, 108 0.74 (0.47–1.16)	0.1984	0.3932	43, 45 2.16 (1.32–3.53)	0.0022	0.0152
AA	49, 71 1.08 (0.71–1.64)	0.7276	0.7018	7, 25 0.64 (0.25–1.48)	0.3272	0.5142	18, 13 3.19 (1.49–7.01)	0.003	0.0203
<i>APEX1_rs3136817</i>									
TT	104, 151 1 (-)			42, 123 0.81 (0.51–1.29)	0.3818	0.5526	54, 57 2.36 (1.44–3.88)	0.0007	0.0056
CT	63, 121 0.76 (0.5–1.15)	0.1921	0.387	26, 81 0.76 (0.44–1.29)	0.3224	0.5105	45, 35 2.98 (1.73–5.19)	0.0001	0.0012
CC	12, 34 0.54 (0.25–1.1)	0.0981	0.2671	7, 23 0.76 (0.29–1.83)	0.564	0.6459	7, 11 1.33 (0.46–3.62)	0.5763	0.6508
<i>ERCC1_rs3212986</i>									
GG	194, 339 1 (-)			49, 132 0.98 (0.65–1.45)	0.9071	0.7458	62, 58 2.81 (1.82–4.35)	<0.001	<0.001
GT	146, 202 1.27 (0.95–1.68)	0.1029	0.2743	25, 82 0.79 (0.47–1.29)	0.3562	0.5353	37, 42 2.31 (1.38–3.84)	0.0013	0.0097
TT	23, 34 1.25 (0.7–2.2)	0.4423	0.5886	1, 13 0.2 (0.01–1.01)	0.1188	0.2984	7, 3 5.92 (1.59–28.18)	0.0118	0.0646
<i>MUTYH_rs3219489</i>									
CC	91, 157 1 (-)			35, 118 0.83 (0.5–1.34)	0.445	0.5901	72, 55 3.69 (2.29–6.01)	<0.001	<0.001
GC	72, 126 0.95 (0.63–1.43)	0.7974	0.7206	31, 94 0.91 (0.54–1.51)	0.7201	0.6996	28, 42 1.93 (1.07–3.46)	0.0281	0.1166
GG	16, 23 1.27 (0.61–2.62)	0.52	0.6271	9, 15 1.93 (0.75–4.74)	0.1584	0.3505	6, 6 2.16 (0.64–7.3)	0.2028	0.3973
<i>ERCC3_rs3738948</i>									
AA	112, 173 1 (-)			46, 139 0.84 (0.54–1.3)	0.4379	0.5862	59, 62 2.33 (1.46–3.74)	0.0004	0.0034
GA	57, 119 0.79 (0.52–1.2)	0.2791	0.4744	24, 79 0.83 (0.47–1.43)	0.5078	0.6216	39, 35 3.17 (1.81–5.58)	0.0001	0.0012
GG	10, 14 1.1 (0.44–2.65)	0.8375	0.7304	5, 9 1.36 (0.4–4.17)	0.5948	0.658	8, 6 3.5 (1.15–11.22)	0.0281	0.1166
<i>ERCC3_XPB_rs4150459</i>									
CC	162, 269 1 (-)			69, 202 0.39 (0.13–0.99)	0.0684	0.2143	98, 95 2.34 (0.82–6.72)	0.1082	0.282
CT	17, 33 0.94 (0.48–1.78)	0.8539	0.7342	5, 24 1.32 (0.05–33.83)	0.8467	0.7325	8, 8 2.59 (1.89–3.55)	<0.001	<0.001
TT	0, 2 –			1, 1 2.9 (1.96–4.33)	<0.001	<0.001	0, 0 –		
<i>KLH4_rs5922437</i>									
GG	101, 172 1 (-)			49, 145 0.88 (0.56–1.36)	0.5582	0.6436	72, 74 2.59 (1.64–4.11)	<0.001	<0.001
AA	26, 62 0.87 (0.5–1.5)	0.624	0.6687	10, 62 0.48 (0.22–0.97)	0.0513	0.1788	27, 22 3.02 (1.57–5.88)	0.001	0.0076
GA	52, 72 0.73 (0.45–1.17)	0.1964	0.3912	16, 20 1.34 (0.63–2.79)	0.439	0.5868	7, 7 1.53 (0.49–4.76)	0.4541	0.5949
<i>XRCC3_Thr241Met_rs861539</i>									
CC	142, 241 1 (-)			19, 87 0.55 (0.31–0.94)	0.0355	0.1381	41, 34 3.05 (1.81–5.2)	<0.001	<0.001
TG	178, 243 1.32 (0.99–1.76)	0.0618	0.2015	43, 103 1.12 (0.72–1.74)	0.6028	0.661	51, 53 2.57 (1.61–4.13)	0.0001	0.0012
TT	43, 91 0.8 (0.52–1.22)	0.3042	0.496	12, 37 0.86 (0.41–1.69)	0.6658	0.6829	14, 16 2.41 (1.1–5.22)	0.0258	0.1106

<sup>a</sup> The reference category for each gene analyzed is having the wild type and being never-smoker.

<sup>a</sup> Adjusted by age, sex and indoor radon exposure.

<sup>b</sup> p-Values.

<sup>c</sup> Corrected p-values.



**Table 4**  
Lung cancer association broken down by radon exposure for the different polymorphisms analyzed.\*

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)					
	Indoor radon exposure (Bq/m3)					
	≤200	p <sup>b</sup>	p-c <sup>c</sup>	> 200	p <sup>b</sup>	p-c <sup>c</sup>
<i>ERCC5_rs1047768</i>						
TC	131, 208 1 (-)			89, 104 1.39 (0.94–2.04)	0.0972	0.2657
CC	86, 146 0.98 (0.68–1.41)	0.9136	0.7472	64, 83 1.34 (0.88–2.05)	0.1737	0.3679
TT	51, 86 0.87 (0.55–1.34)	0.5236	0.6288	25, 50 0.66 (0.37–1.16)	0.1506	0.3411
<i>OGG1_Ser326Cys_rs1052133</i>						
CC	231, 374 1 (-)			160, 203 1.27 (0.97–1.68)	0.0843	0.2444
CG	117, 211 0.87 (0.65–1.17)	0.3637	0.5405	92, 96 1.53 (1.09–2.16)	0.0145	0.075
GG	18, 42 0.64 (0.35–1.15)	0.146	0.3355	11, 20 0.78 (0.34–1.69)	0.5404	0.6361
<i>FATS_C10orf90_rs11245007</i>						
CT	134, 198 1 (-)			73, 103 1.03 (0.69–1.53)	0.8875	0.7416
CC	118, 202 0.82 (0.59–1.15)	0.2559	0.4529	87, 109 1.14 (0.77–1.67)	0.515	0.6249
TT	16, 41 0.57 (0.29–1.08)	0.092	0.2574	18, 25 1.22 (0.6–2.43)	0.5814	0.6528
<i>APEX1_rs1130409</i>						
GT	135, 206 1 (-)			73, 123 1 (0.68–1.47)	0.7598	0.7638
TT	71, 125 1.06 (0.71–1.56)	0.7868	0.7179	54, 62 1.4 (0.89–2.22)	0.1458	0.3352
GG	62, 110 0.94 (0.63–1.42)	0.7834	0.717	51, 52 1.68 (1.04–2.73)	0.0341	0.1341
<i>ERCC1_rs11615</i>						
CC	90, 159 1 (-)			63, 67 1.73 (1.1–2.59)	0.0155	0.0785
CT	137, 261 0.97 (0.69–1.38)	0.8823	0.7405	111, 152 1.34 (0.92–1.94)	0.1257	0.3085
TT	140, 208 1.24 (0.87–1.77)	0.2274	0.4238	90, 100 1.65 (1.1–2.48)	0.0158	0.0796
<i>OGG1_rs125701</i>						
GG	194, 331 1 (-)			134, 166 1.42 (1.04–1.94)	0.0294	0.1198
AG	68, 101 1.1 (0.75–1.6)	0.6224	0.6681	35, 64 0.95 (0.59–1.53)	0.8417	0.7314
AA	6, 8 2.03 (0.63–6.25)	0.2185	0.4141	9, 7 1.73 (0.6–5.12)	0.3085	0.4995
<i>RRM1_rs12806698</i>						
CC	156, 245 1 (-)			92, 143 1.05 (0.74–1.5)	0.7816	0.7166
CA	97, 174 0.87 (0.61–1.22)	0.4099	0.57	73, 78 1.42 (0.94–2.14)	0.0934	0.257
AA	15, 22 1.02 (0.48–2.1)	0.9553	0.7555	13, 16 1.24 (0.55–2.77)	0.6022	0.6608
<i>ERCC2_Lys751Gln_rs13181</i>						
TT	158, 283 1 (-)			114, 143 1.4 (1.01–1.94)	0.0428	0.1581
GT	160, 275 1.02 (0.77–1.36)	0.8886	0.7419	121, 141 1.56 (1.13–2.15)	0.0074	0.0447
GG	49, 70 1.18 (0.77–1.81)	0.4376	0.586	29, 35 1.35 (0.77–2.35)	0.2909	0.4848
<i>rs1452584</i>						
AA	162, 298 1 (-)			119, 167 1.27 (0.91–1.75)	0.1543	0.3456
GA	92, 127 1.23 (0.86–1.75)	0.2559	0.4529	46, 62 1.35 (0.85–2.13)	0.2007	0.3954
GG	14, 16 1.19 (0.54–2.6)	0.6604	0.6811	13, 8 3.04 (1.15–8.48)	0.0273	0.1146

Table 4 (Continued)

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)					
	Indoor radon exposure (Bq/m3)					
	≤200	p <sup>b</sup>	p-c <sup>c</sup>	> 200	p <sup>b</sup>	p-c <sup>c</sup>
<i>ERCC2_Asp312Asn.rs1799793</i>						
TT	153, 280 1 (-)			112, 139 1.52 (1.08–2.14)	0.0162	0.0809
CT	101, 137 1.47 (1.04–2.9)	0.0295	0.1201	56, 87 1.31 (0.86–2.01)	0.2065	0.4008
CC	14, 23 1.2 (0.56–2.51)	0.6323	0.6716	10, 11 1.32 (0.51–3.38)	0.5595	0.6441
<i>NBN.rs1805794</i>						
CC	112, 202 1 (-)			76, 111 1.12 (0.75–1.68)	0.565	0.6463
GC	121, 199 0.98 (0.69–1.39)	0.9223	0.7489	81, 105 1.46 (0.98–2.18)	0.0658	0.2094
GG	35, 40 1.88 (1.09–3.24)	0.0231	0.1031	21, 21 1.91 (0.94–3.88)	0.0724	0.2223
<i>OGG1_C7G.rs2072668</i>						
CC	165, 258 1 (-)			109, 147 1.18 (0.84–1.65)	0.3477	0.5293
CG	88, 153 0.88 (0.62–1.25)	0.4729	0.6047	62, 75 1.28 (0.84–1.94)	0.25	0.4471
GG	15, 28 0.76 (0.38–1.51)	0.4483	0.5918	7, 15 0.63 (0.22–1.66)	0.3646	0.5411
<i>ERCC5.rs2094258</i>						
CC	164, 284 1 (-)			117, 157 1.32 (0.95–1.84)	0.1021	0.2732
CT	84, 131 1.15 (0.8–1.64)	0.4523	0.594	55, 73 1.32 (0.86–2.03)	0.2034	0.3979
TT	20, 25 1.18 (0.6–2.28)	0.6264	0.6695	6, 7 1.16 (0.34–3.9)	0.8081	0.7233
<i>XPC.rs2228001</i>						
GT	135, 217 1 (-)			79, 115 1.15 (0.78–1.69)	0.4692	0.6028
TT	99, 154 1.04 (0.73–1.49)	0.8162	0.7253	63, 80 1.31 (0.86–2)	0.2132	0.4081
GG	34, 70 0.72 (0.43–1.18)	0.1989	0.3936	36, 41 1.25 (0.73–2.13)	0.4123	0.5715
<i>OGG1.rs2472037</i>						
AG	114, 211 1 (-)			88, 106 1.5 (1.01–2.22)	0.0438	0.1606
AA	109, 165 1.14 (0.8–1.62)	0.483	0.6097	66, 97 1.15 (0.76–1.74)	0.5008	0.6183
GG	44, 56 1.44 (0.88–2.34)	0.1471	0.3368	23, 33 1.64 (0.86–3.07)	0.126	0.3089
<i>XRCC1_Gln399Arg.rs25487</i>						
GG	165, 276 1 (-)			120, 140 1.36 (0.98–1.88)	0.0622	0.2023
AG	151, 272 0.91 (0.68–1.21)	0.5177	0.6261	109, 146 1.31 (0.95–1.82)	0.1041	0.2761
AA	51, 80 1.07 (0.7–1.61)	0.7657	0.7124	35, 33 1.7 (1–2.91)	0.0499	0.1756
<i>APEX1.rs3136817</i>						
TT	139, 232 1 (-)			99, 115 1.35 (0.94–1.95)	0.1062	0.2792
CT	107, 158 0.97 (0.68–1.33)	0.8541	0.7342	65, 103 1 (0.66–1.49)	0.9874	0.7616
CC	22, 51 0.69 (0.38–1.21)	0.2077	0.4018	14, 19 1.27 (0.57–2.78)	0.5455	0.6383
<i>ERCC1.rs3212986</i>						
GG	208, 373 1 (-)			152, 181 1.5 (1.12–1.99)	0.0057	0.0359
GT	139, 219 1.15 (0.86–1.52)	0.3395	0.5234	98, 123 1.47 (1.06–2.04)	0.0214	0.098
TT	20, 36 1.08 (0.59–1.94)	0.7928	0.7194	14, 15 1.77 (0.8–3.88)	0.1503	0.3408

Table 4 (Continued)

Polymorphisms	Cases, controls; OR <sup>a</sup> (95%CI)					
	Indoor radon exposure (Bq/m <sup>3</sup> )					
	≤200	p <sup>b</sup>	p-c <sup>c</sup>	> 200	p <sup>b</sup>	p-c <sup>c</sup>
<i>MUTYH</i> .rs3219489						
CC	141, 230 1 (-)			102, 121 1.37 (0.95–1.98)	0.0873	0.2496
GC	100, 176 0.91 (0.64–1.28)	0.5925	0.6571	63, 105 1.08 (0.72–1.61)	0.7206	0.6998
GG	26, 35 1.49 (0.82–2.67)	0.1873	0.3822	12, 10 1.68 (0.65–4.39)	0.2838	0.4786
<i>ERCC3</i> .rs3738948						
AA	160, 262 1 (-)			108, 144 1.19 (0.84–1.67)	0.3193	0.5081
GA	92, 159 0.97 (0.69–1.37)	0.872	0.7383	58, 83 1.29 (0.84–1.96)	0.2395	0.4365
GG	16, 20 1.28 (0.61–2.62)	0.5096	0.6224	12, 10 2 (0.79–5.18)	0.1441	0.3331
<i>ERCC3_XPB</i> .rs4150459						
CC	244, 399 1 (-)			162, 205 1.29 (0.97–1.71)	0.0762	0.2296
CT	24, 38 0.92 (0.51–1.61)	0.7645	0.712	15, 31 0.83 (0.41–1.59)	0.5796	0.6521
TT	0, 2 -			1, 1 1.69 (0.07–43.58)	0.714	0.6978
<i>KLH4</i> .rs5922437						
GG	170, 287 1 (-)			115, 135 1.5 (1.07–2.1)	0.019	0.0903
AA	47, 96 0.96 (0.62–1.46)	0.8355	0.7299	36, 59 1.14 (0.69–1.88)	0.5947	0.658
GA	51, 57 1.16 (0.72–1.89)	0.5392	0.6356	27, 43 0.82 (0.46–1.45)	0.4993	0.6176
<i>XRCC3</i> .Thr241Met.rs861539						
CC	132, 238 1 (-)			106, 136 1.41 (1–1.99)	0.052	0.1804
TG	181, 283 1.21 (0.9–1.63)	0.1983	0.3931	125, 137 1.79 (1.28–2.51)	0.0008	0.0063
TT	54, 107 0.92 (0.61–1.37)	0.6708	0.6845	32, 45 1.2 (0.71–2.02)	0.4967	0.6164

<sup>a</sup> The reference category for each gene analyzed is having the wild type and being exposed to a radon concentration < 200 Bq/m<sup>3</sup>.

<sup>a</sup> Adjusted by age, sex and tobacco consumption.

<sup>b</sup> p-Values.

<sup>c</sup> Corrected p-values.

important amount of never-smokers from the LCRINS study (Lung Cancer Association in Never Smokers), where this histological type is the most frequent. Nevertheless, this fact favoured that we had the same percentage of cases of each sex (50% each), allowing for a better interpretation of the results both for men and women.

This study has also a number of advantages. First, the sample size is relatively large, and we have been able to include information regarding the second association factor of lung cancer, which is indoor radon exposure. This is of particular importance because there is a lack of information on the mechanisms of radon causing lung cancer. It is important to note that Galicia is a radon prone-area<sup>32,33</sup> and the median time that cases and controls have been living at the same residence is high enough to induce lung cancer. Finally, the high participation rate and the multicentric nature of this research increase the external validity of its results.

In conclusion, these findings support that polymorphisms located in BER and NER pathways do not have an association with lung cancer onset, with the exception of the gene NBN (rs1805794). Nevertheless, this study support the hypothesis of their role modulating the effect of tobacco consumption, where heavy smokers might have their lung cancer association modulated by polymorphisms located in the BER and NER pathways. This could also

happen for those individuals having high indoor radon exposures though at a minor extent.

### Financial support

This work was funded by a competitive research grant offered by the Xunta de Galicia [10CSA2080057PR] “Risk factors of lung cancer in never smokers: a multicenter case-control study in the Northwest of Spain”, partially supported by the Instituto de Salud Carlos III [PI13/01765]. “Molecular genetic profile of DNA repair markers (BER and NER) and biological risk of lung cancer from residential radon exposure: A case-control study”, partially supported by Instituto de Salud Carlos III, Ministry of Science and Innovation of Spain [PI15/01211]. (Year 2015) and another from the same institution [PI031248] (Year 2012). “Residential Radon Exposure, Histologic Types, and Lung Cancer Risk. A Case-Control Study in Galicia, Spain”.

### Conflict of interests

Dr. Kelsey is a founder and scientific advisor for Cellintec, which had no role in this research.

The authors declare no conflict of interests.

## Acknowledgments

The genotyping service was accomplished at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I+D+I 2013–2016, funded by ISCIII and ERDF.

## References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021; <http://dx.doi.org/10.3322/caac.21660>.
- Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. *Surg Oncol Clin N Am*. 2016;25:439–45. <http://dx.doi.org/10.1016/j.soc.2016.02.001>.
- US Environmental Protection Agency. A citizen's Guide to Radon: the guide to protecting yourself and your family from radon. Washington: US Environmental Protection Agency; 2016.
- World Health Organization. WHO handbook on indoor radon: a public health perspective. Geneva, Switzerland: World Health Organization; 2009. p. 94.
- Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ*. 2005;330:223. <http://dx.doi.org/10.1136/bmj.38308.477650.63>.
- Ruano-Ravina A, Pereyra MF, Castro MT, Pérez-Ríos M, Abal-Arca J, Barros-Dios JM. Genetic susceptibility residential radon, and lung cancer in a radon prone area. *J Thorac Oncol*. 2014;9:1073–80. <http://dx.doi.org/10.1097/jto.0000000000000205>.
- Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provençio M, Parente-Lamelas I, et al. Residential radon, genetic polymorphisms in DNA damage and repair-related. *Lung Cancer*. 2019;135:10–5. <http://dx.doi.org/10.1016/j.lungcan.2019.07.003>.
- Weng M, Lee H-W, Park S-H, Hu Y, Wang H-T, Chen L-C, et al. Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. *Proc Natl Acad Sci USA*. 2018;115:E6152–61. <http://dx.doi.org/10.1073/pnas.1804869115>.
- Munnia A, Giese RW, Polvani S, Galli A, Cellai F, Peluso MEM. Bulky DNA adducts, tobacco smoking genetic susceptibility, and lung cancer risk. *Adv Clin Chem*. 2017;81:231–77. <http://dx.doi.org/10.1016/bs.acc.2017.01.006>.
- Wiencke JK. DNA adduct burden and tobacco carcinogenesis. *Oncogene*. 2002;21:7376–91. <http://dx.doi.org/10.1038/sj.onc.1205799>.
- Paz-Elizur T, Leitner-Dagan Y, Meyer KB, Markus B, Giorgi FM, O'Reilly M, et al. DNA repair biomarker for lung cancer risk and its correlation with airway cells gene expression. *JNCI Cancer Spectr*. 2020;4:pkz067. <http://dx.doi.org/10.1093/jncics/pkz067>.
- Scharer OD. Nucleotide excision repair in eukaryotes. *Cold Spring Harb Perspect Biol*. 2013;5. <http://dx.doi.org/10.1101/cshperspect.a012609>, a012609-a012609.
- Krokan HE, Bjoras M. Base excision repair. *Cold Spring Harb Perspect Biol*. 2013;5. <http://dx.doi.org/10.1101/cshperspect.a012583>, a012583-a012583.
- Harfe BD, Jinks-Robertson S. DNA mismatch repair and genetic instability. *Annu Rev Genet*. 2000;34:359–99. <http://dx.doi.org/10.1146/annurev.genet.34.1.359>.
- Felicitas López-Cima M, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Puente XS, et al. Polymorphisms in XPC, XPD XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain. *BMC Cancer*. 2007;7:162. <http://dx.doi.org/10.1186/1471-2407-7-162>.
- Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provençio M, Parente-Lamelas I, et al. Lung cancer risk and residential radon exposure: a pooling of case-control studies in northwestern Spain. *Environ Res*. 2020;189:109968. <http://dx.doi.org/10.1016/j.envres.2020.109968>.
- Nusbaum C, Zody MC, Borowsky ML, Kamal M, Kodira CD, Taylor TD, et al. DNA sequence and analysis of human chromosome 18. *Nature*. 2005;437:551–5. <http://dx.doi.org/10.1038/nature03983>.
- MacBean RS, Hyland CA, Flower RL. Blood group genotyping: the power and limitations of the Hemo ID Panel and MassARRAY platform. *Immunohematology*. 2015;31:75–80.
- Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provençio M, Parente-Lamelas I, et al. Lung cancer and residential radon in never-smokers: a pooling study in the Northwest of Spain. *Environ Res*. 2019;172:713–8. <http://dx.doi.org/10.1016/j.envres.2019.03.011>.
- Torres-Durán M, Ruano-Ravina A, Parente-Lamelas I, Leiro-Fernández V, Abal-Arca J, Montero-Martínez C, et al. Lung cancer in never-smokers: a case-control study in a radon-prone area (Galicia Spain). *Eur Respir J*. 2014;44:994–1001. <http://dx.doi.org/10.1183/09031936.00017114>.
- Qin H, Zhu J, Zeng Y, Du W, Shen D, Lei Z, et al. Aberrant promoter methylation of hOGG1 may be associated with increased risk of non-small cell lung cancer. *Oncotarget*. 2017;8:8330–41. <http://dx.doi.org/10.18632/oncotarget.14177>.
- Zhu J, Hua R-X, Jiang J, Zhao L-Q, Sun X, Luan J, et al. Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis. *PLoS ONE*. 2014;9:e97616. <http://dx.doi.org/10.1371/journal.pone.0097616>.
- Yu T, Xue P, Cui S, Zhang L, Zhang G, Xiao M, et al. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression. *Cancer Med*. 2018;7:6317–30. <http://dx.doi.org/10.1002/cam4.1842>.
- Chuang C-L, Wang C-H, Hsu C-H, Hsiao C-L, Chen G-L, Yen S-T, et al. Contribution of double-strand break repair gene Nijmegen breakage syndrome 1 genotypes gender difference and smoking status to Taiwanese lung cancer. *Anticancer Res*. 2017;37:2417–23. <http://dx.doi.org/10.21873/anticancer.11581>.
- Charlotta R, Kumar R, Thirumaran RK, Hou S-M. Polymorphisms in the DNA repair genes XRCC1, APEX1 XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. *Lung Cancer*. 2006;54:285–92. <http://dx.doi.org/10.1016/j.lungcan.2006.08.004>.
- Wang L, Cheng J, Gao J, Wang J, Liu X, Xiong L. Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systematic review and meta-analysis. *Mol Biol Rep*. 2013;40:2711–5. <http://dx.doi.org/10.1007/s11033-012-2358-5>.
- He Y-Z, Chi X-S, Zhang Y-C, Deng X-B, Wang J-R, Lv W-Y, et al. NBS1 Glu185Gln polymorphism and cancer risk: update on current evidence. *Tumor Biol*. 2014;35:675–87. <http://dx.doi.org/10.1007/s13277-013-1093-4>.
- Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1 RAD51C, and RAD51D results on patient management and adherence to provider recommendations. *Cancer*. 2020;126:549–58. <http://dx.doi.org/10.1002/cncr.32572>.
- Marchand LL, Donlon T, Lum-Jones A, Seifried A, Wilkens LR. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2002;39:11249–62.
- Wei W, He X-F, Qin J-B, Su J, Li S-X, Liu Y, et al. Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis. *Mol Biol Rep*. 2012;39:11249–62. <http://dx.doi.org/10.1007/s11033-012-2035-8>.
- Torres-Durán M, Ruano-Ravina A, Parente-Lamelas I, Abal-Arca J, Leiro-Fernández V, Montero-Martínez C, et al. Alpha-1 antitrypsin deficiency and lung cancer risk: a case-control study in never-smokers. *J Thorac Oncol*. 2015;10:1279–84. <http://dx.doi.org/10.1097/jto.0000000000000609>.
- Lorenzo-González M, Ruano-Ravina A, Peón J, Piñeiro M, Barros-Dios JM. Residential radon in Galicia: a cross-sectional study in a radon-prone area. *J Radiol Prot*. 2017;37:728–41. <http://dx.doi.org/10.1088/1361-6498/aa7922>.
- Barros-Dios JM, Ruano-Ravina A, Gastelu-Iturri J, Figueiras A. Factors underlying residential radon concentration: results from Galicia Spain. *Environ Res*. 2007;103:185–90. <http://dx.doi.org/10.1016/j.envres.2006.04.008>.